Quick answer: No. Trazodone is not included in standard 5-, 10- or 12-panel urine drug tests. However, its metabolite m-CPP can occasionally cause a false-positive on amphetamine or MDMA immunoassays. Any non-negative screen should be confirmed by GC-MS or LC-MS/MS and reviewed with a medical review officer.
- Trazodone is not a target analyte on common instant urine cups or dip cards.
- Rare cross-reactivity with amphetamine/MDMA screens is documented, so a presumptive positive is not a final result.
- Lab confirmation and a documented medication review protect both the donor and your program.
What Trazodone Is and Why It Comes Up
Trazodone is a prescription antidepressant, also widely prescribed at low doses for sleep (see MedlinePlus, Trazodone). Because it is so common, collection sites, probation officers and HR teams see it on medication disclosure lists often. The question is whether it changes a drug screen result.
Need drug tests for your clinic, program or workplace?
American Screening Corp has supplied FDA-cleared, CLIA-waived tests at wholesale pricing since 2004. Popular options:
Ordering 100+ tests? Request volume pricing.
What Standard Drug Tests Detect
Instant urine tests are immunoassays built to detect specific drug classes. Federal workplace testing under the HHS Mandatory Guidelines (SAMHSA) covers marijuana (THC), cocaine, opiates, phencyclidine, and amphetamines including MDMA. Trazodone is not on that list, and common non-regulated panels (benzodiazepines, barbiturates, methadone, oxycodone and similar) do not target it either.
For reference, the federal initial test cutoff for amphetamines in urine is 500 ng/mL, with a confirmatory cutoff of 250 ng/mL for amphetamine and methamphetamine (SAMHSA, Mandatory Guidelines for Federal Workplace Drug Testing Programs). Non-federal panels may use different cutoffs, so always read the package insert of the specific device.
The False-Positive Risk: m-CPP
Trazodone is metabolized in part to meta-chlorophenylpiperazine (m-CPP). Published case reports describe m-CPP cross-reacting with some amphetamine and MDMA immunoassays, producing a presumptive positive in a donor who took only trazodone. This is uncommon and varies by manufacturer and antibody, but it is well enough known that programs should plan for it.
A confirmatory method such as GC-MS or LC-MS/MS identifies the actual molecule and separates amphetamine or MDMA from m-CPP. That is why a screen alone should never drive adverse action.
Scenarios at a Glance
| Scenario | Likely result | Recommended action |
|---|---|---|
| Donor takes trazodone, standard panel without amphetamines | Negative for all panel drugs | Record result; no further action |
| Donor takes trazodone, panel includes amphetamine/MDMA | Usually negative; occasional presumptive positive | Send to lab for confirmation |
| Presumptive positive, confirmation finds no amphetamine or MDMA | Reported negative by lab | Close out as negative; document |
| Confirmation finds amphetamine or MDMA | Confirmed positive | Route to MRO or your policy's review process |
How to Read Results Step by Step
- Check the device is within expiration and the control line appears.
- Read at the time stated in the package insert; do not interpret lines after the window.
- Treat any line-absent test region as a presumptive positive for that drug only, not a final finding.
- Ask about prescriptions only in the manner your policy allows, and keep disclosures confidential.
- Send the specimen for laboratory confirmation before any decision.
Choosing Testing Supplies
For on-site screening, drug test cups offer integrated collection and temperature strips, while drug test dip cards suit high-volume or budget-conscious programs. Whichever format you buy, confirm the panel, cutoff levels and the device's FDA clearance and CLIA-waived status in the manufacturer's documentation, and pair it with a lab confirmation process. For DOT-regulated employees, follow 49 CFR Part 40, which requires MRO verification of all laboratory results.
Program Checklist
- Define in policy that all non-negative screens require lab confirmation.
- Confirm which panel and cutoffs each device uses before purchase.
- Train staff to read results within the stated time window.
- Use a medical review step for legitimate prescriptions.
- Keep medication disclosures separate from general personnel files.
- Document chain of custody for every specimen sent to the lab.
- Review lot numbers and expiration dates at each reorder.
Questions about panels or confirmation workflows? Contact American Screening Corp; we supply wholesale testing products to clinics, treatment centers, courts, staffing firms and employers from Shreveport, Louisiana.
Frequently Asked Questions
Does trazodone show up on a standard urine drug test?
No. Trazodone is not a target of standard 5-, 10- or 12-panel urine tests. Only a specialized lab method designed to find it would detect the drug itself.
Can trazodone cause a false positive for amphetamines?
Rarely. The metabolite m-CPP has been reported to cross-react with some amphetamine and MDMA immunoassays. Confirmation by GC-MS or LC-MS/MS resolves it.
What should an employer do after a presumptive positive?
Do not act on the screen alone. Send the specimen for lab confirmation and use a medical review process so a donor can document a valid prescription.
Should we ask every donor about trazodone?
Not before the test. Follow your written policy and applicable law, and handle any medication disclosure during the review step, kept confidential. For related hiring checks, see Reveal Background.
Sources
- MedlinePlus: Trazodone
- SAMHSA: Workplace Drug Testing and Mandatory Guidelines
- U.S. DOT ODAPC: 49 CFR Part 40
This article is general information, not legal or medical advice.
